Table 1

 Key features of included studies

TrialPatientsExperimental group treatmentControl group treatmentAge (years)Male (%)Ischemic heart failure (%)Baseline LVEF (%)Follow-up (months)Outcomes reported*
ANZ13415CarvedilolPlacebo67808829191,2,3,4,5
BEST142708BucindololPlacebo60775823361,2,3,4,5
Bristow et al15139BucindololPlacebo5662292631,2,3,4,5
CARMEN16381CarvedilolEnalapril627768<40221,2,4
Carvedilol Efficacy/Cohn et al17105CarvedilolPlacebo6054442261,4,5
CHRISTMAS18387CarvedilolPlacebo6290893061,4,5
CIBIS19641BisoprololPlacebo60835625231,2,3,4
CIBIS II202647BisoprololPlacebo61815028161,2,3,4
CIBIS III211010BisoprololEnalapril72666129241,4
Colucci et al22366CarvedilolPlacebo55864423121,3,4,5
COMET103029CarvedilolMetoprolol62795126581,2,3,4
COPERNICUS232289CarvedilolPlacebo63796720101,4
ENECA24260NebivololPlacebo72706025121,2,4,5
MERIT HF 2000 and 200225,263991MetoprololPlacebo64776528121,4
MOCHA/Bristow et al27345CarvedilolPlacebo6076522361,2,3,4
Packer et al281094CarvedilolPlacebo58774823121,2,3,4
PRECISE29278CarvedilolPlacebo5974502261,4,5
RESOLVD30426MetoprololPlacebo6279692861,2,4,5
SENIORS312128NebivololPlacebo76726936211,2,3,4
Sturm et al32100AtenololPlacebo51873117241,2,3,4
Waagstein et al-MDC33383MetoprololPlacebo4975NA22181,3,4,5

LVEF=left ventricular ejection fraction.

*1=death; 2=cardiovascular death; 3=sudden death; 4=drug discontinuation; 5=change in LVEF (%).